ASH 2023 | Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses a study (NCT04116437) assessing the efficacy of zanubrutinib, a next-generation BTK inhibitor (BTKi), in patients with B-cell malignancies who are intolerant to acalabrutinib. Zanubrutinib shows efficacy without causing high-grade adverse events (AEs), making it a promising BTKi for patients who need an alternative to acalabrutinib. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, Fate Therapeutics, Janssen, Kite, a Gilead Company, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, ADC therapeutics, Genentech, AbbVie, MEI Pharma, Regeneron; Research Funding: BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, Vincerx, Genentech, AbbVie, TG Therapeutics.
